Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-flutemetamol PET in ATTR Cardiomyopathy
NCT05374564Phase 1Completed
- Sponsor
- Yale University
- Start
- Aug 2022
- Primary completion
- Nov 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by Yale University. Primary endpoints: Association of ATTR cardiomyopathy disease severity with increased 18F-flutemetamol uptake at 6 months and Reduction of 18F-flutemetamol cardiac PET imaging markers after tafamidis treatment at 6 months. Started Aug 2022; status: completed.
Beyond the preview
Go deeper on NCT05374564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05374564.